DRG have produced a range of ELISAs that can be applied in a range of diagnostic tests, including diabetes, tumor marking and hypertension. This brochure details the range and applications of their ELISA assays.
High Quality Assays with Reproducible and Reliable Results
With the Sperm Antibody Haemagglutination Test the titer of sperm antibodies is detected in human serum.Antibodies directed against spermatozoa antigens may cause infertility in women or men. The application of the Spermatozoa Antibody Haemagglutination Test is recommended for the diagnosis of immunologically caused disorders of fertility. Unwanted childlessness is a growing problem with which up to 20% of all couples in the reproductive age areconfronted temporarily or long-term. In 20% of these cases the presence of anti-spermatozoa antibodies in the male or the female patient is detectable (Lahteenmaki A et al: Hum Reprod (1995) 10, 2824-28; Nagy ZP et al: Hum Reprod (1995) 10, 1775-80). The definition of infertility according to the WHO (WHO Laboratory Manual for the Examination of Human Semen and Semen Cervical-Mucus Interaction, 1999) is the absence of a conception within 12 months of unprotected intercourse. The main cause of an immunological fertility disorder is the formation of antibodies directed against spermatozoa antigens. Anti-spermatozoa antibodies exert heterogeneous effects on the ability of spermatozoa to fertilize. The inhibiting effect of anti-spermatozoa antibodies on the motility of spermatozoa by binding to their surface and by agglutinating processes is well-known (Zouari R et al: Fertil Steril (1993) 59, 606-12). The penetration of the spermatozoa into the cervical mucus is impaired by the presence of anti-spermatozoa antibodies in the seminal plasma and/or in the cervical mucus (Eggert-Kruse W et al: Hum Reprod (1993) 8, 1025-31). Anti-spermatozoa antibodies negatively influence the capacitation and the acrosome reaction ofspermatozoa and thereby impede the interaction of the spermatozoa with the oocyte (Francavilla F et al: Front Biosci (1999): 1;4:9-25; Bohring C et al.: Hum Reprod (2001) 7:113-8). The interaction of the spermatozoon with the oocyte and the subsequent binding to and penetration of the zona pellucida may be inhibited by anti-spermatozoa antibodies. The following fusion of the oocyte and a spermatozoon may also be impaired by the presence of anti-spermatozoa antibodies (Mazumdar S et al.: Fertil Steril (1998) 70, 799-810; Kutteh WH: Hum Reprod, (1999) 14, 2426-9). According to Crosignani et al. (Crosignani et al.: PG et al.: Hum Reprod (1998) 13, 2025-32) the rate of pregnancies in couples with anti-spermatozoa antibodies on the part of the man or the woman are 38% lower compared to the control groups. Furthermore an influence on the implantation and on the early embryological development could be confirmed. An association of anti-spermatozoa antibodies and miscarriages is discussed. The frequency of anti-spermatozoa antibodies in infertile couples amounts to 20% (Lahteenmaki A et al.: Hum Reprod (1995) 10, 2824-28; Nagy ZP et al.: Hum Reprod (1995) 10, 1775-80). Anti-spermatozoa antibodies may occur dissolved in the ejaculate or bound to the surface of spermatozoa. Antispermatozoa antibodies may be found in men and in women (Clarke GN et al.: Am J Reprod Immunol Microbiol (1985) 7, 143-7). In women anti-spermatozoa antibodies may be found in cervical mucus, oviduct liquid and follicular liquid. Men having more than 50% of their spermatozoa coated with anti-spermatozoa antibodies show a conspicuously reduced rate of fertility (Abshagen K et al.: Fertil Steril (1998) 70, 355-6).The Sperm Antibody Haemagglutination Test can be applied in the clinical practice for the diagnosis immunologically caused infertility in men and in women.The test is based on the haemagglutination test principle using sensitised red blood cells (sSRBC) of sheep as target antigen. Antibodies in the samples agglutinate with sSRBC within 90 minutes.
With the Ovary Antibody Haemagglutination Test the titer of ovary antibodies is detected in human serum.Antibodies directed against ovary antigens in serum can cause infertility in women. The application of the Ovary Antibody Haemagglutination Test is recommended for monitoring disorders of fertility and premature ovarian failure.The Ovary Antibody Haemagglutination Test can be applied in the clinical practice for the confirmation or the exclusion of antibodies against ovarial tissues as the cause of fertility problems.The test is based on the haemagglutination test principle using sensitised red blood cells (sSRBC) of sheep as target antigen. Antibodies in the samples agglutinate with sSRBC within 90 minutes.
When a woman becomes pregnant, her body produces a hormone called hCG (human Chorionic Gonadotropin). The secretion of this hormone by the developing placenta begins soon after conception and increases throughout the first trimester. The presence of hCG in the urine is an excellent indication in the early detection of pregnancy. The hCG Home Pregnancy Test is a rapid qualitative test for the determination of human Chorionic Gonadotropin (hCG) in urine. The test utilizes unique antibodies that are specific for hCG, enabling it to be a highly sensitive and accurate test. With DRG’s hCG Test, pregnancy can be determined as early as the first day of a woman's missed period.
High Quality Assays with Reproducible and Reliable Results
High Quality Assays with Reproducible and Reliable Results
High Quality Assays with Reproducible and Reliable Results
High Quality Assays with Reproducible and Reliable Results
High Quality Assays with Reproducible and Reliable Results
This product is intended for in vitro diagnostic use in the quality control of immunoassays using saliva samples.The Control Set can be used for:SLV-4409 DHEA-S (Salivary) ElisaSLV-3653 Estriol free (Salivary) ELISASLV-4780 Androstenedione (Salivary) ELISA
This Pregnancy Test Kit contains everything you need to determine if you are pregnant. Testing is done in one simple step, and you see the result in 5 minutes. With this kit you can test as early as the first day of your missed period.When a woman becomes pregnant, her body produces a hormone called hCG (human Chorionic Gonadotropin). The secretion of this hormone by the developing placenta begins soon after conception, and increases throughout the first trimester. The presence of hCG in the urine is an excellent indication in the early detection of pregnancy. DRG’s HCG test is a rapidqualitative test for the detection of human Chorionic Gonadotropin (hCG) in urine. With the test's high sensitivity, pregnancy can be detected as early as the first day of a woman's missed period.
This Ovulation Predictor Test is a rapid test used for the detection of Luteinizing Hormone (LH) in urine to predict your time of ovulation. What Is Ovulation?Ovulation is the release of an egg from your ovaries. You are most likely to become pregnant in the few days around your ovulation. Your body makes a substance called Luteinizing Hormone (LH) that triggers the release of the egg. During most of your menstrual cycle, your body only makes a little LH. But around the middle of your cycle, yourbody suddenly increases the amount of LH for a few days. This sudden increase is called the “LH surge,” and it usually causes you to ovulate. Ovulation usually takes place within 40 hours after the LH surge begins. You should understand that you might not have an LH surge or might not ovulate every menstrual cycle. Even if your menstrual bleeding begins when you expect it to, that does not necessarily mean that you have ovulated. After ovulation, the amount of LH in your body will return to its normal level within 2 days. Unless you get pregnant, this cycle of increase and decrease of LH will repeat again after your menstrual period ends.
High Quality Assays with Reproducible and Reliable Results
High Quality Assays with Reproducible and Reliable Results
High Quality Assays with Reproducible and Reliable Results
High Quality Assays with Reproducible and Reliable Results
High Quality Assays with Reproducible and Reliable Results
High Quality Assays with Reproducible and Reliable Results
High Quality Assays with Reproducible and Reliable Results
High Quality Assays with Reproducible and Reliable Results
High Quality Assays with Reproducible and Reliable Results
High Quality Assays with Reproducible and Reliable Results
High Quality Assays with Reproducible and Reliable Results
The Troponin I Rapid Test is a rapid immunoassay for measurement of Cardiac Troponin I (cTnI) in human whole blood, serum and plasma specimen. The Troponin I Rapid Test is an immunchromatography assay for measurement of cTnI in whole blood, serum and plasma. The membrane strip contains one test line and one control line; streptavidin for biotinylated cTnI antibody and rabbit anti-goat IgG antibody for the control line. A dye pad is placed at the end of the membrane containing biotinylated cTnI antibody and gold colloidal particles coupled with cTnI antibody. When a sample is applied into the sample well, the cardiac makers present in the sample bind to the specific antibodies coupled with gold particles. cTnI in a sample binds to both cTnI specific dye coupled antibody and biotinylated antibody. The immune complexes move along the nitrocellulose membrane through the test lines and bind to streptavidin immobilized on the test line. Unbound immune complexes pass through the test line and are captured by goat anti mouse antibody in the control line. If the concentration of this marker in the sample is above the cut-off level, red bands appear at the corresponding test lines and the control line. If the concentration of the marker in the sample is lower than the cut-off level, only the colored control line can be seen in the test window. This colored control band must always appear at the control line position (C) for valid test results. A test result is not valid if the colored control line does not appear in the test window.
The test is based on the immunological capture of colored microparticles as they move along a membrane on which the monoclonal antibody has been immobilized.Entamoeba Ag Rapid Test (RAP-5405 and RAP-5406) use monoclonal antibodies specific for Entamoeba histolytica that detect all forms of the parasite during its life cycle. The test is based on the use of red microspheres covalently linked to an anti-Entamoeba histolytica monoclonal antibody, plus blue microspheres as test control. The parasites present in stool samples react with the latex particles which are coated with specific monoclonal antibodies against the antigen. This latex particles/antibodies/parasite complex migrates through a chromatographic process towards the reaction area. In this area, anti-Entamoeba histolytica antibodies that react with the latex particles/antibodies/parasite complex are present. This reaction leads to the appearance of a red line. These lines are used to interpret the result after a five-minute incubation at room temperature.
The Rota / Adenovirus chromatographic immunoassay (RAP-5543 cassettes, RAP-5544 strips) is a procedure for the in vitro qualitative detection of Rotavirus and Adenovirus antigens in human stool. Rotaviruses are the main cause of acute gastroenteritis, particularly in children under two years of age. Its discovery in 1973 and its association with child gastroenteritis represented a breakthrough in the study of gastroenteritis not due to acute bacterial infection. Transmission occurs through the fecal-oral route; the incubationperiod is between 1 and 3 days. Adenoviruses are the second leading cause of viral gastroenteritis in children (10 -15%); they can also cause respiratory diseases and depending on the serotype, diarrhea, conjunctivitis, cystitis, and others. At least 47 adenovirus serotypes have been identified and in all of them the hexon antigen is present. Serotypes 40 and 41 are associated with gastroenteritis. The main clinical symptom of gastroenteritis caused by adenovirus is diarrhea, for 9 to 12 days, also occurring with fever and vomiting. Thetest is based on the immunological capture of colored microbeads during its passage along a membrane on which the monoclonal antibody has been immobilized.The cassettes or strip Rota-Adenovirus test uses a combination of: 1) monoclonal antibodies against VP6 antigen of group A rotavirus, conjugated to red latex particles and specific monoclonal antibodies to rotavirus on the membrane. 2) monoclonal antibodies against adenovirus hexon antigen (present in all adenovirus subtypes), conjugated to blue latex particles and specific monoclonal antibodies to adenovirus on the membrane. In this test, the sample is previously treated with a sample diluent to extract the rotavirus andadenovirus antigens present in the stool. After the extraction, the extract is simply added to the reaction device. When the extract flows through the test membrane, the colored particles migrate. In the event of a positive result, specific antibodies on the membrane will capture the colored particles. Depending on the virus content of the sample, different colored lines will be visible. These lines are used for interpretation of results, following a five-minute incubation at room temperature.
The Rota / Adenovirus chromatographic immunoassay (RAP-5543 cassettes, RAP-5544 strips) is a procedure for the in vitro qualitative detection of Rotavirus and Adenovirus antigens in human stool. Rotaviruses are the main cause of acute gastroenteritis, particularly in children under two years of age. Its discovery in 1973 and its association with child gastroenteritis represented a breakthrough in the study of gastroenteritis not due to acute bacterial infection. Transmission occurs through the fecal-oral route; the incubation period is between 1 and 3 days. Adenoviruses are the second leading cause of viral gastroenteritis in children (10 -15%); they can also cause respiratory diseases and depending on the serotype, diarrhea, conjunctivitis, cystitis, and others. At least 47 adenovirus serotypes have been identified and in all of them the hexon antigen is present. Serotypes 40 and 41 are associated with gastroenteritis. The main clinical symptom of gastroenteritis caused by adenovirus is diarrhea, for 9 to 12 days, also occurring with fever and vomiting. The test is based on the immunological capture of colored microbeads during its passage along a membrane on which the monoclonal antibody has been immobilized.The cassettes or strip Rota-Adenovirus test uses a combination of: 1) monoclonal antibodies against VP6 antigen of group A rotavirus, conjugated to red latex particles and specific monoclonal antibodies to rotavirus on the membrane. 2) monoclonal antibodies against adenovirus hexon antigen (present in all adenovirus subtypes), conjugated to blue latex particles and specific monoclonal antibodies to adenovirus on the membrane. In this test, the sample is previously treated with a sample diluent to extract the rotavirus and adenovirus antigens present in the stool. After the extraction, the extract is simply added to the reaction device. When the extract flows through the test membrane, the colored particles migrate. In the event of a positive result, specific antibodies on the membrane will capture the colored particles. Depending on the virus content of the sample, different colored lines will be visible. These lines are used for interpretation of results, following a five-minute incubation at room temperature.
The RapidBZO test is an immunochromatography based one step in vitro test. It is designed for qualitative determination of Benzodiazepines and their metabolites in human urine specimens above a cut-off level of 300-ng/ml oxazepam. This assay has not been evaluated in the point of care location and is for use by Healthcare Professionals only. This assay provides only a preliminary analytical test result. A more specific alternative chemical method must be used in order to obtain a confirmed analytical result. The Substance AbuseMental Health Services Administration (SAMHSA) has established gas chromatography/ mass spectrometry (GC/MS) as the preferred confirmatory method. Clinical consideration and professional judgment should be applied to any drug of abuse test result, particularly when preliminary positive results are indicated. Benzodiazepines are a class of widely prescribed central nervous system depressants, which have anxiolytic, hypnotic, anticonvulsant and muscle relaxant effects. Chronic abusecan result in addiction and tardive dyskinnesia. Acute higher doses lead to drowsiness, dizziness, muscle relaxation, lethargy, and coma and possible death. The effects of benzodiazepines use last 4 – 8 hours. Many of the benzodiazepines share a common metabolic route, and are excreted as oxazepam and its glucuronide in urine. Oxazepam is detectable in the urine for up to 7 days after drug use. However, the length of time following drug use for which a positive result may occur is dependent upon several factors, including the frequency and amount of drug, metabolic rate, excretion rate, drug half-life, and the drug user’s age, weight, activity and diet. The RapidBZO test is based on the principle ofspecific immunochemical reaction between antibodies and antigens to analyzeparticular compounds in human urine specimen. The assay relies on thecompetition for binding antibody between drug conjugate and free drug, whichmay be present in the urine specimen being tested. When drug is present in the urine specimen,it competes with drug conjugate for the limited amount of antibody-dyeconjugate. When the amount of drug is equal or more than the cut-off, 300 ng/mlof oxazepam, it will prevent the binding of drug conjugate to the antibody.Therefore, a positive urine specimen will not show a colored band on the testline zone, indicating a positive result, while the presence of a colored bandindicates a negative result. A controlline is present in the test window to work as procedural control. This coloredband should always appear on the control line zone if the test device is storedin good condition and the test is performed appropriately.
The QuickScreen™ One Step THC Screening Test is a rapid, qualitative immunoassay for the detection of the THC metabolite (THCA) and other cannabinoid compounds in urine. The cutoff for this test is 50 ng/mL, as recommended by the Substance Abuse and Mental Health Services Administration (SAMHSA), formerly the U.S. National Institute of Drug Abuse (NIDA). This assay is intended for professional use. This test provides only a preliminary test result. A more specific alternate testing method must be used in order to obtain a confirmed analytical result. Gas chromatography/mass spectrometry (GC/MS) is the preferred confirmatory method. Other chemical confirmation methods are available. Clinical consideration and professional judgment should be applied to any drug of abuse test result, particularly when preliminary positive results are observed.Δ9-Tetrahydrocannabinol (THC) is generally accepted to be the principle active component in marijuana, although other cannabinoids are likely to contribute to the physiological activity of marijuana. Tetrahydrocannabinol is rapidly absorbed by inhalation and the gastrointestinal tract. It is almost completely metabolized. The predominant metabolite, 11-Nor-Δ9-THC-2- carboxylic Acid (or THCA), is found in the plasma, feces and urine along with other compounds. Very low concentrations of THC may be detected in urine during the initial several hours, but THCA persists in urine at a detectable concentration for many days after smoking. Urine based screening tests for drugs of abuse range from complex analytical procedures to simple immunoassay tests. The sensitivity and rapidity of immunoassays have made them the most accepted method of preliminary screening for drugs of abuse in urine. This allows the laboratory to eliminate the large number of negative specimens and focus on the smaller number of initially positive samples.The QuickScreen™ One Step THC Screening Test is a competitive immunoassay that is used to screen for the presence of THCA in urine. It is a chromatographic absorbent device in which drugs or drug metabolites in a sample compete with drug / protein conjugate immobilized on a porous membrane for a limited number of antibody / dye conjugate binding sites. The test device employs a unique combination of monoclonal and polyclonal antibodies to selectively identify THCA and other cannabinoid compounds in urine with a high degree of confidence. In the procedure, the absorbent end of the test device is inserted into the urine sample. The urine is absorbed into the device by capillary action, mixes with the antibody / dye conjugate, and flows across the pre-coated membrane. When THCA levels are below 50 ng/mL (the detection sensitivity of the test), antibody / dye conjugate binds to the drug / protein conjugate immobilized in the Test Region (T) of the device. This produces a colored Test Band that, regardless of its intensity, indicates a negative result. When THCA levels are at or above 50 ng/mL, the free drug in the sample binds to the antibody / dye conjugate, preventing the antibody / dye conjugate from binding to the drug / protein conjugate immobilized in the Test Region (T) of the device. This prevents the development of a distinct colored band, indicating a potentially positive sample. In either case, a colored Control Band is produced in the Control Region (C) by a non-specific antibody-dye / conjugate reaction. This band serves as a built-in quality control device that demonstrates antibody recognition and reactivity as well as confirmation that the test is complete.
The QuickScreenTM One Step Phencyclidine Screening Test is a rapid, qualitative immunoassay for the detection of Phencyclidine in urine. The cutoff concentration for this test is 25 ng/mL, as recommended by the Substance Abuse and Mental Health Services Administration (SAMHSA), formerly the U.S. National Institute of Drug Abuse (NIDA). This test provides only a preliminary test result. A more specific alternate testing method must be used in order to obtain a confirmed analytical result. Gas chromatography/mass spectrometry (GC/MS) is the preferred confirmatory method. Other chemical confirmation methods are available. Clinical consideration and professional judgment should be applied to any drug of abuse test result, particularly when preliminary positive results are observed.Phencyclidine, commonly known as PCP or “angel dust,” is used primarily as a recreational drug for its hallucinogenic effects. PCP is commonly taken orally, by inhalation, by insufflation or intravenously. It is well absorbed following all routes of administration, concentrating fastest in fatty tissues and the brain. Unchanged PCP is excreted in the urine in moderate amounts (10% of the dose). The terminal half-life for PCP varies considerably, with a range of 8 - 55 hours, averaging of 18 hours. The effects of PCP are unpredictable and variable. Depending on the amount used, the user may show signs of euphoria, relaxation, increased strength, time and space distortions, anxiety, panic, and hallucination. Urine based screening tests for drugs of abuse range from complex analytical procedures to simple immunoassay tests. The sensitivity and rapidity of the immunoassays have made them the most accepted method of preliminary screening for drugs of abuse in urine. This allows the laboratory to eliminate the large number of negative specimens and focus on the smaller number of initially positive specimens. The QuickScreenTM One Step Phencyclidine Test is a competitive immunoassay that is used to screen for the presence of Phencyclidine in urine. It is a chromatographic absorbent device in which drugs or drug metabolites in a sample compete with drug / protein conjugate immobilized on a porous membrane for a limited number of antibody /dye conjugate binding sites. The test device employs a unique combination of monoclonal and polyclonal antibodies to selectively identify Phencyclidine in urine with a high degree of confidence. In the assay procedure, a urine sample is added to the test device in the Sample Well “S,” where it is absorbed into the device by capillary action. The urine mixes with the antibody-dye conjugate and flows across the pre-coatedmembrane. When sample PCP levels are below 25 ng/mL (the detection sensitivity of the test), antibody / dye conjugate binds to the drug / protein conjugate immobilized in the Test Region (T)of the device. This produces a colored Test Band that, regardless of its intensity, indicates a negative result. When sample PCP levels are at or above 25 ng/mL, the free drug in the sample binds to the antibody / dye conjugate, preventing the antibody / dye conjugate from binding to the drug / protein conjugate immobilized in the Test Region (T) of the device. This prevents the development of a distinct colored band, indicating a potentially positive sample. In either case, a colored Control Band is produced in the Control Region (C) by a non-specific antibody-dye / conjugate reaction. This band serves as a built-in quality control device that demonstrates antibody recognition and reactivity as well as confirmation that the test is complete.
The QuickScreenTM One Step Benzodiazepines Screening Test is a rapid, qualitative immunoassay for the detection of Benzodiazepines in urine at a cutoff concentration of 200 ng/mL. This assay is intended for use in clinical toxicology laboratories, physicians’ offices, drug-of-abuse clinics, law enforcement agencies and on-site workplace drug testing programs. This test provides only a preliminary test result. A more specific alternate testing method must be used in order to obtain a confirmed analytical result. Gas chromatography/mass spectrometry (GC/MS) is the preferred confirmatory method. Other confirmation methods are available. Clinical consideration and professional judgment should be applied to any drug-of-abuse test result, certainly when preliminary positive results are observed.Benzodiazepines form one of the largest classes of abused pharmaceuticals. These products are sedative/hypnotics and anti-anxiety drugs that produce a calming effect, thus they are often prescribed as tranquilizers. Frequently abused Benzodiazepines include Alprazolam (Xanax®), Diazepam (Valium®), Lorazepam (Ativan®), Triazolam (Halcion®), Chlordiazepoxide (Librium®), Flurazepam (Dalmane®) and Temazepam (Restoril®). A trend has been observed in the past several years of abuse of these legitimate pharmaceuticals in conjunction with illicit controlled substances such as methadone and heroin. Benzodiazepines may be detected for up to two weeks in urine. Urine-based screening tests for drugs of abuse range from complex analytical procedures to simple immunoassay tests. The sensitivity and rapidity of immunoassays have made them the most accepted method of preliminary screening for drugs of abuse in urine. This allows the laboratory to eliminate the large number of negative specimens and focus on the smaller number of initially positive samples.The QuickScreenTM One Step Benzodiazepines Screening Test is a competitive immunoassay that is used to screen for the presence of Benzodiazepines in urine. It is a chromatographic absorbent device in which drugs or drug metabolites in a sample compete with drug / protein conjugate immobilized on a porous membrane for a limited number of antibody /dye conjugate binding sites. The test device employs a unique combination of monoclonal and polyclonal antibodies to selectively identify Benzodiazepines in urine with a high degree of confidence. In the procedure, urine is added to the test device in the Sample Well where it is absorbed into the device by capillary action. The urine mixes with the antibody / dye conjugate and flows across the pre-coated membrane. When sample Benzodiazepine levels are below 200 ng/mL (the detection sensitivity of the test), antibody / dye conjugate binds to the drug / protein conjugate immobilized in the Test Region (T) of the device. This produces a colored Test Band that, regardless of its intensity, indicates a negative result. When sample Benzodiazepine levels are at or above 200 ng/mL, the free drug in the sample binds to the antibody / dye conjugate, preventing the antibody / dye conjugate from binding to the drug / protein conjugate immobilized in the Test Region (T) of the device. This prevents the development of a distinct colored band, indicating a potentially positive sample. In either case, a colored Control Band is produced in the Control Region (C) by a non-specific antibody-dye / conjugate reaction. This band serves as a built-in quality control device that demonstrates antibody recognition and reactivity as well as confirmation that the test is complete.
The QuickScreen One Step THC Screening test is a rapid, qualitative immunoassay for detection of Tetrahydrocannabinol and other cannabinoid compounds in urine. The cutoff concentration for this test is 50 ng/ml, as recommended by the Substance Abuse and Mental Health Services Administration (SAMHSA), formerly the U.S. National Institute of Drug Abuse (NIDA). This assay is intended for use in clinical toxicology laboratories, physician's offices, drug-of-abuse clinics and law enforcement agencies. This test provides only a preliminary test result. A more specific alternate testing method must be used in order to obtain a confirmed analytical result. Gas chromatography / mass spectrometry (GC/MS) is the preferred confirmatory method. Other chemical confirmation methods are available. Clinical consideration and professional judgment should be applied to any drug of abuse test result, particularly when preliminary positive results are observed.Tetrahydrocannabinol (THC) is generally accepted to be the principle active component in marijuana. Inhalation and the gastrointestinal tract rapidly absorb tetrahydrocannabinol. It is almost completely metabolized. The predominant metabolite, 11-Nor-Δ9-THC-9-carboxylic Acid (or THCA), is found in the plasma, feces and urine along with other compounds. Very low concentrations of THC may be detected in urine during the initial several hours, but THCA persists in urine at a detectable concentration for many days after smoking. Urine based screening tests for drug of abuse range from complex analytical procedures to simple immunoassay tests. The sensitivity and rapidity of immunoassays have made them the most accepted method of preliminary screening for drugs of abuse in urine. This allows the laboratory to eliminate the large number of negative specimens and focus on the smaller number of initially positive samples.The QuickScreen One Step THC test is a competitive immunoassay that is used to screen for the presence of THC in urine. It is a chromatographic absorbent device in which drug or drug metabolites in a sample compete with drug/protein conjugate immobilized on a porous membrane for a limited number of antibody/dye conjugate binding sites. The test device employs a unique combination of monoclonal and polyclonal antibodies to selectively identify THC in urine with a high degree of confidence. In the assay procedure, a urine sample is added to the test device in the Sample Well with the aid of a plastic transfer pipette. The urine is absorbed into the device by capillary action. The urine mixes with the antibody/dye conjugate, and flows across the pre-coated membrane. When sample THC levels are below 50 ng/ml (detection sensitivity of the test) antibody/dye conjugate binds to the drug/protein conjugate immobilized in the test region (T) of the device. This produces a colored Test Band that, regardless of its intensity, indicates a negative result. When sample THC levels are at or above 50 ng/ml, the free drug in the sample binds to the antibody/Dye conjugate immobilized in the Test Region (T) of the device. This prevents the development of a distinct colored band. This indicates a potentially positive sample. In either case, a colored band Control Band is produced in the Control Region (C) by a non-specific antibody/dye/conjugate reaction. This band serves as a built-in quality control device that demonstrates antibody recognition and reactivity as well as confirmation that the test is complete.
The QuickScreen One Step Phencyclidine Test is a rapid, qualitative immunoassay for the detection of Phencyclidine in urine. The cutoff concentration for this test is 25 ng/ml, as recommended by the Substance of Abuse and Mental Health Services Administration (SAMHSA), formerly the U.S. National Institute of Drug Abuse (NIDA). This test provides only a preliminary test result. A more specific alternate testing method must be used in order to obtain a confirmed analytical result. Gas chromatography/mass spectrometry (GC/MS) is the preferred confirmatory method. Other confirmation methods are available. Clinical consideration and professional judgment should be applied to any drug-of-abuse test result, particularly when preliminary positive results are observed.Phencyclidine, commonly known as PCP or "angel dust", is used primarily as a recreational drug for its hallucinogenic effect. PCP is commonly taken orally, by inhalation, by insufflation or intravenously. It is well absorbed following all routes of administration, concerning fastest in fatty tissues and the brain. Unchanged PCP is excreted in the urine in moderate amounts (10% of the dose). The terminal half-life for PCP varies considerably, with a range of 8-55 hours, averaging of 18 hours. The effects of PCP are unpredictable and variable. Depending on the amount used, the user may show signs of euphoria, relaxation, increased strength, time and space distortions, anxiety, panic, and hallucination.QuickScreenÔ One Step PCP Screening Test is a competitive immunoassay that is used to screen for the presence of Phencyclidine in urine. It is a chromatographic absorbent device in which drugs or drug metabolites in a sample compete with drug/protein conjugate immobilized on a porous membrane for a limited number of antibody/dye conjugate binding sites. The test device employs a unique combination of monoclonal and polyclonal antibodies to selectively identify PCP in urine with a high degree of confidence. A test strip is inserted into a sample cup containing the urine specimen. The urine then migrates up the strip by capillary action. As it migrates it mixes with labeled antibody/dye mixture. When no PCP is present in a sample, or the PCP concentration is below 25 ng/ml (the detection sensitivity of the test), antibody/dye conjugate binds to drug/protein conjugate coated in the Test Region (T) of the device. This reaction produces a color5ed Test Band which, regardless of its intensity, indicates a negative result. When the PCP urine concentration is at or above 25 ng/ml, antibody/dye conjugate binds to free drug, competing with the drug/protein conjugate in the test region (T) of the device for the limited number of antibody binding sites. This prevents the development of a distinct colored band, indicating a potentially positive sample. In either case, a colored Control Band is produced in the Control Region (C) by a non-specific antibody-dye/conjugate reaction. This band serves as a built-in quality control device, demonstrating generic antibody recognition and reactivity as well as confirming that the test result is valid.
The QuickScreen One Step Opiates Screening Test is a rapid, qualitative immunoassay for the detection of opiates and opiate metabolites in urine. The cutoff concentration for this test is 300 ng/mL, as recommended by the Substance Abuse and Mental Health Services Administration (SAMHSA), formerly the U.S. National Institute of Drug Abuse (NIDA). This test provides only a preliminary test result. A more specific alternate testing method must be used in order to obtain a confirmed analytical result. Gas chromatography/mass spectrometry (GC/MS) is the preferred confirmatory method. Other chemical confirmation methods are available. Clinical consideration and professional judgment should be applied to any drug of abuse test result, particularly when preliminary positive results are observed.Opiates are addictive, pain-relieving narcotic drugs derived from the opium poppy (Papaver somniferum). An opiate is any natural or synthetic drug derived from this plant that has morphine-likepharmacological actions. Natural opiates include Morphine, Codeine and Thebaine. Synthetic opiates include Heroin, Hydrocodone and Levorphanol. Urine based screening tests for drugs of abuse range from complex analytical procedures to simple immunoassay tests. The sensitivity and rapidity of immunoassays have made them the most accepted method of preliminary screening for drugs of abuse in urine. This allows the laboratory to eliminate the large number of negative specimens and focus on the smaller number of initially positive specimens. The QuickScreen One Step Opiates Screening Test is a competitive immunoassay that is used to screen for the presence of Opiates and their metabolites in urine. It is a chromatographic absorbent device in which drugs or drug metabolites in a sample compete with drug / protein conjugate immobilized on a porous membrane for a limited number of antibody / dye conjugate binding sites. The test device employs a unique combination of monoclonal and polyclonal antibodies to selectively identify Opiates and their metabolites in urine with a high degree of confidence. In the assay procedure, a urine sample is added to the test device in the Sample Well “S,” where it is absorbed into the device by capillary action. The urine mixes with the antibody-dye conjugate and flows across the pre-coated membrane. When sample Opiate levels are below 300 ng/mL (the detection sensitivity of the test), antibody / dye conjugate binds to the drug/ protein conjugate immobilized in the Test Region (T) of the device. This produces a colored Test Band that, regardless of its intensity, indicates a negative result. When sample Opiate levels are at or above 300 ng/mL, the free drug in the sample binds to the antibody / dye conjugate, preventing the antibody / dye conjugate from binding to the drug / protein conjugate immobilized in the Test Region (T) of the device. This prevents the development of a distinct colored band,indicating a potentially positive sample.
The QuickScreen One Step Opiates Screening Test is a rapid, qualitative immunoassay for the detection of opiates and opiate metabolites in urine. The cutoff concentration for this test is 300 ng/mL, as recommended by the Substance Abuse and Mental Health Services Administration (SAMHSA), formerly the U.S. National Institute of Drug Abuse (NIDA). This test provides only a preliminary test result. A more specific alternate testing method must be used in order to obtain a confirmed analytical result. Gas chromatography/mass spectrometry (GC/MS) is the preferred confirmatory method. Other chemical confirmation methods are available. Clinical consideration and professional judgment should be applied to any drug of abuse test result, particularly when preliminary positive results are observed.Opiates are addictive, pain-relieving narcotic drugs derived from the opium poppy (Papaver somniferum). An opiate is any natural or synthetic drug derived from this plant that has morphine-likepharmacological actions. Natural opiates include Codeine, Morphine and Thebaine. Synthetic opiates include Heroin, Hydrocodone and Levorphanol. Urine based screening tests for drugs of abuse range from complex analytical procedures to simple immunoassay tests. The sensitivity and rapidity of immunoassays have made them the most accepted method of preliminary screening for drugs of abuse in urine. This allows the laboratory to eliminate the large number of negative specimens and focus on the smaller number of initially positive specimens. The QuickScreen One Step Opiates Screening Test is a competitive immunoassay that is used to screen for the presence of Opiates and their metabolites in urine. It is a chromatographic absorbent device in which drugs or drug metabolites in a sample compete with drug / protein conjugate immobilized on a porous membrane for a limited number of antibody / dye conjugate binding sites. The test device employs a unique combination of monoclonal and polyclonal antibodies to selectively identify Opiates and their metabolites in urine with a high degree of confidence. In the procedure, the absorbent end of the device is inserted in the urine sample. Urine is absorbed into the device by capillary action, mixes with the antibody / dye conjugate and flows across the pre-coated membrane. When sample Opiate levels are below 300 ng/mL (the detection sensitivity of the test), antibody / dye conjugate binds to the drug / protein conjugate immobilized in the Test Region (T) of the device. This produces a colored Test Band that, regardless of its intensity, indicates a negative result. When sample Opiate levels are at or above 300 ng/mL, the free drug in the sample binds to the antibody / dye conjugate, preventing the antibody / dye conjugate from binding to the drug/ protein conjugate immobilized in the Test Region (T) of the device. This prevents the development of a distinct colored band, indicating a potentially positive sample. In either case, a colored Control Band is produced in the Control Region (C) by a non-specific antibody-dye / conjugate reaction. This band serves as a built-in quality control device, demonstrating antibody recognition and reactivity, as well as confirming that the test is complete.
The QuickScreen One Step Methadone Screening Test is a rapid, qualitative immunoassay for the detection of Methadone in urine. The cutoff concentration for this test is 300 ng/ml. This assay is intended for professional use. This test provides only a preliminary test result. A more specific alternate testing method must be used in order to obtain a confirmed analytical result. Gas chromatography/mass spectrometry (GC/MS) is the preferred confirmatory method. Other confirmation methods are available. Clinical consideration and professional judgment should be applied to any drug-of-abuse test results.Methadone is a synthetic opioid, clinically available in the US since 1947. It acts on the central nervous system and cardiovascular systems producing respiratory and circulatory depression. It also produces meiosis and increases the tone of smooth muscle in the lower gastrointestinal tract while decreasing the amplitude of contractions. Methadone ismetabolized in the liver by N-demethylation to form the metabolites 2-Ethylidene-1,5-Dimethyl-3,3-Diphenylpyrrolidine (EDDP) and 2-Ethyl-5-Methyl-3,3-Diphenylpyrrolidine (EMDP). These and the parent drug undergo hydroxylation with subsequent conjugation with glucuronid acid. All are excreted in bile and are the major products measured after methadone administration. Excretion rates vary from 5 to 50% of a dose in 24 hours, dependent on urine volume, pH, dosage and metabolism rate. Methadone is used clinically for treatment of severe pain and in treatment programs for morphine and heroin addiction. Urine-based screening tests for drugs of abuse range from complex analytical procedures to simple immunoassay tests. The sensitivity and rapidity of immunoassays have made them the most accepted method of preliminary screening for drugs of abuse in urine. This allows the laboratory to eliminate a large number of negative specimens and focus on the smaller number of initially positive samples.QuickScreen One Step Methadone Screening Test is a competitive immunoassay that is used to screen for the presence of Methadone in urine. It is a chromatographic absorbent device in which drugs or drug metabolites in a sample compete with drug/protein conjugate immobilized on a porous membrane for a limited number of antibody/dye conjugate binding sites. The test device employs a unique combination of monoclonal and polyclonal antibodies to selectively identify Methadone in urine with a high degree of confidence.In the procedure, the absorbent end of the test device is inserted into the urine sample. The urine is absorbed into the device by capillary action, mixes with the antibody / dye conjugate, and flows across the pre-coated membrane. When sample Methadone levels are below 300 ng/ml (the detection sensitivity of the test), antibody/dye conjugate binds to thedrug/protein conjugate immobilized in the Test region (T) of the device. This produces a colored Test Band that, regardless of its intensity, indicates a negative result. When sample Methadone levels are at or above 300 ng/ml, the free drug in the sample binds to the antibody/dye conjugate, preventing the antibody/dye conjugate from binding to the drug/protein conjugate immobilized in the Test Region (T) of the device. This prevents the development of a distinct colored band, indicating a potentially positivesample.
The QuickScreen One Step Methadone Screening Test is a rapid, qualitative immunoassay for the detection of Methadone in urine. The cutoff concentration for this test is 300 ng/ml. This assay is intended for professional use. This test provides only a preliminary test result. A more specific alternate testing method must be used in order to obtain aconfirmed analytical result. Gas chromatography/mass spectrometry (GC/MS) is the preferred confirmatory method. Other confirmation methods are available. Clinical consideration and professional judgment should be applied to any drug-of-abuse test results.Methadone is a synthetic opioid, clinically available in the US since 1947. It acts on the central nervous system and cardiovascular systems producing respiratory and circulatory depression. It also produces meiosis and increases the tone of smooth muscle in the lower gastrointestinal tract while decreasing the amplitude of contractions. Methadone is metabolized in the liver by N-demethylation to form the metabolites 2-Ethylidene-1,5-Dimethyl-3,3-Diphenylpyrrolidine (EDDP) and 2-Ethyl-5-Methyl-3,3-Diphenylpyrrolidine (EMDP). These and the parent drug undergo hydroxylation with subsequent conjugation with glucuronid acid. All areexcreted in bile and are the major products measured after methadone administration. Excretion rates vary from 5 to 50% of a dose in 24 hours, dependent on urine volume, pH, dosage and metabolism rate. Methadone is used clinically for treatment of severe pain and in treatment programs for morphine and heroin addiction. Urine-based screening tests for drugs of abuse range from complex analytical procedures to simple immunoassay tests. The sensitivity and rapidity of immunoassays have made them the most accepted method of preliminary screening for drugs of abuse in urine. This allows the laboratory to eliminate a large number of negative specimens and focus on the smaller number of initially positive samples.The QuickScreen One Step Methadone Screening Test is a competitive immunoassay that is used to screen for the presence of Methadone in urine. It is a chromatographic absorbent device in which drug or drug metabolites in a sample compete with drug/protein conjugate immobilized on a porous membrane for a limited number of antibody/dye conjugate binding sites. The test device employs a unique combination of monoclonal and polyclonal antibodies to selectively identify Methadone in urine with a high degree of confidence.In the procedure, urine is added to the test device’s “SAMPLE” well with the aid of a plastic transfer pipette. The urine is absorbed into the device by capillary action, mixes with the antibody / dye conjugate, and flows across the pre-coated membrane. When sample Methadone levels are below 300 ng/ml (the detection sensitivity of the test), antibody/dye conjugate binds to the drug/protein conjugate immobilized in the Test region (T) of the device. This produces a colored Test Band that, regardless of its intensity, indicates a negative result. When sample Methadone levels are at or above 300 ng/ml, the free drug in the sample binds to the antibody/dye conjugate, preventing the antibody/dye conjugate from binding to the drug/protein conjugate immobilized in the Test Region (T) of the device. This prevents the development of a distinct colored band, indicating a potentially positive sample. In either case, a colored Control Band is produced in the Control Region (C) by a non-specific antibody-dye/conjugate reaction. This band serves as a built-in quality control device that demonstrates antibody recognition and reactivity as well as confirmation that the test result is valid.
The QuickScreen One Step Metamphetamine Test is a rapid, qualitative immunoassay for the detection of (+)- Metamphetamine in urine. The cutoff concentration for this test is 500 ng/ml, as recommended by the U.S. Department of Defense and adopted by U.S. Laboratory Certification Program. This corresponds to the Substance Abuse and Mental Health Services Administration (SAMHSA) recommendation for the confirmation test cutoff for GC/MS [8]. This test provides only a preliminary test result. A more specific alternate testing method must be used in order to obtain a confirmed analytical result. Gas chromatography/mass spectrography (GC/MS) is the preferred confirmatory method. Other chemical confirmation methods are available. Clinical consideration and professional judgment should be applied to any drug-of-abuse test results, certainly when preliminary positive results are observed.(+)-Methamphetamine and its metabolites are central nervous system stimulants whose pharmacological properties include alertness, wakefulness, increased energy, reduced hunger and an overall feeling of well being. Large doses and extended usage can result in higher tolerance levels and physiological dependency. Urine based screening tests for drugs of abuse range from complex analytical procedures to simple immunoassay tests. The sensitivity and rapidity of immunoassays have made them the most accepted method of preliminary screening for drugs of abuse in urine. This allows the laboratory to eliminate the large number of negative specimens and focus on the smaller number of initially positive specimens.QuickScreen One Step Methamphetamine Test is a competitive immunoassay that is used to screen for the presence of (+)-Metamphetamine in urine. It is a chromatographic absorbent device in which drug or drug metabolites in a sample compete with drug/protein conjugate immobilized on a porous membrane for a limited number of antibody/dye conjugate binding sites. The test device employs a unique combination of monoclonal and polyclonal antibodies to selectively identify (+)-Methamphetamine in urine with a high degree of confidence. In the procedure, urine is added to the test device in the Sample Well with the aid of a plastic transfer pipette. The urine is absorbed into the device by capillary action, mixes with the antibody/dye conjugate, and flows across the pre-coated membrane. When Metamphetamine levels are below 500 ng/ml (the detection sensitivity of the test), antibody / dye conjugate binds to the drug/protein conjugate immobilized in the Test Region (T) of the device. This produces a colored Test Band that, regardless of its intensity, indicates a negative result. When sample Methamphetamine levels are at or above 500 ng/ml, free drug in the sample binds to the antibody/dye conjugate, preventing the antibody / dye conjugate from binding to the drug / protein conjugate immobilized in the Test Region. This prevents the development of a distinct colored Test Band, indicating a potentially positive sample. In either case, a colored Control Band is produced in the Control Region (C) by a non-specific antibody-dye/conjugate reaction. This band serves as a built-in quality control device that demonstrates antibody recognition and reactivity as well as confirmation that the test is complete.
The QuickScreen One Step Metamphetamine Test is a rapid, qualitative immunoassay for the detection of (+)- Metamphetamine in urine. The cutoff concentration for this test is 500 ng/ml, as recommended by the U.S. Department of Defense and adopted by U.S. Laboratory Certification Program. This corresponds to the Substance Abuse and Mental Health Services Administration (SAMHSA) recommendation for the confirmation test cutoff for GC/MS [8]. This test provides only a preliminary test result. A more specific alternate testing method must be used in order to obtain a confirmed analytical result. Gas chromatography/mass spectrography (GC/MS) is the preferred confirmatory method. Other chemical confirmation methods are available. Clinical consideration and professional judgement should be applied to any drug-of-abuse test results, certainly when preliminary positive results are observed.(+)-Methamphetamine and its metabolites are central nervous system stimulants whose pharmacological properties include alertness, wakefulness, increased energy, reduced hunger and an overall feeling of well being. Large doses and extended usage can result in higher tolerance levels and physiological dependency. Urine based screening tests for drugs of abuse range from complex analytical procedures to simple immunoassay tests. The sensitivity and rapidity of immunoassays have made them the most accepted method of preliminary screening for drugs of abuse in urine. This allows the laboratory to eliminate the large number of negative specimens and focus on the smaller number of initially positive specimens.QuickScreen One Step Methamphetamine Test is a competitive immunoassay that is used to screen for the presence of (+)-Metamphetamine in urine. It is a chromatographic absorbent device in which drug or drug metabolites in a sample compete with drug/protein conjugate immobilized on a porous membrane for a limited number of antibody/dye conjugate binding sites. The test device employs a unique combination of monoclonal and polyclonal antibodies to selectively identify (+)-Methamphetamine in urine with a high degree of confidence. In the procedure, urine is added to the test device in the Sample Well with the aid of a plastic transfer pipette. The urine is absorbed into the device by capillary action, mixes with the antibody/dye conjugate, and flows across the pre-coated membrane. When Metamphetamine levels are below 500 ng/ml (the detection sensitivity of the test), antibody / dye conjugate binds to the drug/protein conjugate immobilized in the Test Region (T) of the device. This produces a colored Test Band that, regardless of its intensity, indicates a negative result. When sample Methamphetamine levels are at or above 500 ng/ml, free drug in the sample binds to the antibody/dye conjugate, preventing the antibody / dye conjugate from binding to the drug / protein conjugate immobilized in the Test Region. This prevents the development of a distinct colored Test Band, indicating apotentially positive sample. In either case, a colored Control Band is produced in the Control Region (C) by a non-specific antibody-dye/conjugate reaction. This band serves as a built-in quality control device that demonstrates antibody recognition and reactivity as well as confirmation that the test is complete.
The QuickScreen One Step Cocaine Screening Test is a rapid, qualitative immunoassay for the detection of Benzoylecgonine, a hydrolytic degradation product, in urine. The cutoff concentration for this test is 300 ng/ml, as recommended by the Substance Abuse and Mental Health Services Administration (SAMHSA), formerly the U.S. National Institute of Drug Abuse (NIDA). This test provides only a preliminary test result. A more specific alternate testing method must be used in order to obtain a confirmed analytical result. Gas chromatography/mass spectrometry (GC/MS) is the preferred confirmatory method. Other confirmation methods are available. Clinical consideration and professional judgement should be applied to any drug-of-abuse test results, certainly when preliminary positive results are observed.Cocaine is an alkaloid present in coca leaves (Eryrthroxine coca) whose pharmacological properties include alertness, wakefulness, increased energy and an overall feeling of euphoria6. Cocaine has been used medicinally as a local anesthetic, however its addictive properties have minimized its modern value as an anesthetic5. Elimination of cocaine is predominantly controlled by its biotransformation. Very low concentrations of cocaine may be detected in urine during the initial several hours, but Benzoylecgonine persists in urine at detectable concentrations for 48 hrs. Urine-based screening tests for drugs of abuse range from complex analytical procedures to simple immunoassay tests. The sensitivity and rapidity of immunoassays have made them the most accepted method of preliminary screening for drugs of abuse in urine. This allows the laboratory to eliminate the large number of negative specimens and focus on the smaller number of initially positive specimens.QuickScreen™ One Step Cocaine Screening Test is a competitive immunoassay that is used to screen for the presence of Benzoylecgonine in urine. It is a chromatographic absorbent device in which drug or drug metabolites in a sample compete with drug conjugate immobilized on a porous membrane for a limited number of binding sites. The test device employs a unique combination of monoclonal and polyclonal antibodies to selectively identify Benzoylecgonine in urine with a high degree of confidence. In the assay procedure, urine is added to the test device in the Sample Well with a plastic transfer pipette. Urine is absorbed into the device by capillary action, mixes with the antibody/dye conjugate and flows across the coated membrane. When Benzoylecgonine levels are below 300 ng/ml (the detection sensitivity of the test), antibody/dye conjugate binds to free drug/protein conjugate immobilized in the Testregion (T) of the device. This produces the development of a distinct color band that regardless of its intensity indicates a negative result. When Benoylecgonine levels are at or above 300 ng/ml, the free drug in the sample binds to the antibody/dye conjugate, preventing the antibody/dye conjugate from binding to the drug/protein conjugate immobilized in the Test Region (T) of the device. This prevents the development of a distinct color band, indicating a potentially positive sample. In either case, a colored Control Band is produced in the Control Region (C) by a non-specific antibody-dye/conjugate reaction. This band serves as a built-in quality control device that demonstrates antibody recognition and reactivity as well as confirmation that the test is complete.
The QuickScreen One Step Benzodiazepines is a rapid, qualitative immunoassay for the detection of Benzodiazepines in urine at a cutoff concentration of 200 ng/ml. This assay is intended for use in clinical toxicology laboratories, physician's offices, and drug of abuse clinics, law enforcement agencies and on-site workplace drug testing programs. This test provides only a preliminary test result. A more specific alternate testing method must be used in order to obtain a confirmed analytical result. Gas chromatography/mass spectrometry (GC/MS) is the preferred confirmatory method. Other confirmation methods are available. Clinical consideration and professional judgement should be applied to any drug-of-abuse test results, certainly when preliminary positive results are observed.Benzodiazepines form one of the largest classes of abused pharmaceuticals. These products are sedative/hypnotics and anti-anxiety drugs that produce calming effects, thus they are often prescribed as tranquilizers. Frequently abused Benzodiazepines include Alprazolam (Xanax), Diazepam (Valium), Lorazepam (Ativan), Triazolam (Halcion), Chlordiazepoxide (Librium), Flurazepam (Dalmane) and Temazepam (Restoril). A trend has been observed in the past several years of abuse of these legitimat pharmaceuticals in conjunction with illicit controlled substances such as methadone and heroin. Benzodiazepines may be detected for up to two weeks in urine. Urine-based screening tests for drugs of abuse range from complex analytical procedures to simple immunoassay tests. The sensitivity and rapidity of immunoassays have made them the most accepted method of preliminary screening for drugs of abuse in urine. This allows the laboratory to eliminate the large number of negative specimens and focus on the smaller number of initiallypositive samples.QuickScreen One Step Benzodiazepines Screening Test is a competitive immunoassay that is used to screen for the presence of Benzodiazepines in urine. It is a chromatographic absorbent device in which drug or drug metabolites in a sample compete with drug/protein conjugate immobilized on a porous membrane for a limited number of antibody/dye conjugate binding sites. The test device employs a unique combination of monoclonal and polyclonal antibodies to selectively identify Benzodiazepines in urine with a high degree of confidence. In the assay procedure, the absorbent end of the device is inserted into the urine sample. The urine is absorbed into the device by capillary action, mixes with the antibody-dye conjugate and flows across the pre-coated membrane. When sample Benzodiazepine levels are below 200 ng/ml (the detection sensitivity of the test), antibody/dyeconjugate binds to the drug/protein conjugate immobilized in the Testregion (T) of the device. This produces a colored Test Band that, regardless of its intensity, indicates a negative result. When sample Benzodiazepine levels are at or above 200 ng/ml, the free drug in the sample binds to the antibody/dye conjugate immobilized in the Test Region (T) of the device. This prevents the development of a distinct colored band, indicating a potentially positive sample. In either case, a colored Control Band is produced in the Control Region (C) by a non-specific antibodydye/conjugate reaction. This band serves as a built-in quality control device that demonstrates antibody recognition and reactivity as well as confirmation that the test is complete.
The QuickScreen One Step Barbiturates Screening Test is a rapid, qualitative immunoassay for the detection of Barbiturate compounds in urine. This assay is calibrated to react with Secobarbital at a cutoff concentration of 200 ng/ml. Other Barbiturates also react (see the “Cross-Reacting Substances” section of this test instructions heet). This assay is intended for professional use. This test provides only a preliminary test result. A more specific alternate testing method must be used in order to obtain a confirmed analytical result. Gas chromatography/mass spectrometry (GC/MS) is the preferred confirmatory method. Other confirmation methods are available. Clinical consideration and professional judgement should be applied to any drug-ofabuse test results, certainly when preliminary positive results are observed.Barbiturates form a large class of abused pharmaceuticals. These products are anxiolytic, sedative/hypnotic, anti-convulsant and anesthetic drugs. As CNS depressants, barbiturates exert effect on excitatory and inhibitory synaptic neurotransmission. Ultra short-acting barbiturates used for anesthesia, such as Pentobarbital, depress excitatory neuronal transmission to a greater extent than anti-convulsant barbiturates such a Phenobarbital. Barbiturates are rapidly and completely absorbed with nearly 100% bioavailability. Short-acting barbiturates are primarily excreted in urine as metabolites, while long-acting barbiturates are primarily excreted unchanged. Ratios of drugs to metabolites and focus on the smaller excreted vary, dependent upon duration of action. Urine-based screening tests for drugs of abuse range from complex analytical procedures to simple immunoassay tests. The sensitivity and rapidity of immunoassays have made them the most accepted method of preliminary screening for drugs of abuse in urine. This allows the laboratory to eliminate the large number of negative specimens and focus on the smaller number of initially positive samples.QuickScreen One Step Barbiturates Screening Test is a competitive immunoassay that is used to screen for the presence of Barbiturates in urine. It is a chromatographic absorbent device in which drug or drug metabolites in a sample compete with drug/protein conjugate immobilized on a porous membrane for a limited number of antibody/dye conjugate binding sites. The test device employs a unique combination of monoclonal and polyclonal antibodies to selectively identify Barbiturates in urine with a high degree of confidence. In the procedure, the absorbent end of the test device is inserted into the urine sample. The urine is absorbed into the device by capillary action, mixes with the antibody / dye conjugate, and flows across the pre-coated membrane. When sample Barbiturate levels are below 200 ng/ml (the detection sensitivity of the test), antibody/dyeconjugate binds to the drug/protein conjugate immobilized in the Testregion (T) of the device. This produces a colored Test Band that, regardless of its intensity, indicates a negative result. When sample Barbiturates levels are at or above 200 ng/ml, the free drug in the sample binds to the antibody/dye conjugate immobilized in the Test Region (T) of the device. This prevents the development of a distinct colored band, indicating a potentially positive sample. In either case, a colored Control Band is produced in the Control Region (C) by a non-specific antibodydye/conjugate reaction. This band serves as a built-in quality control device that demonstrates antibody recognition and reactivity as well as confirmation that the test result is valid.
The QuickScreen One Step Amphetamine Test is a rapid, qualitative immunoassay for the detection of Amphetamine in urine. The cutoff concentration for this test is 1,000 ng/mL, as recommended by the Substance Abuse and Mental Health Services Administration (SAMHSA), formerly the U.S. National Institute of Drug Abuse (NIDA). This test provides only a preliminary test result. A more specific alternate testing method must be used in order to obtain a confirmed analytical result. Gas chromatography/mass spectrometry (GC/MS) is the preferred confirmatory method. Other chemical confirmation methods are available. Clinical consideration and professional judgment should be applied to any drug of abuse test result, particularly when preliminary positive results are observed.Amphetamine and its metabolites are central nervous system stimulants whose pharmacological properties include alertness, wakefulness, increased energy, reduced hunger and an overall feeling of well being. Large doses and extended usage can result in higher tolerance levels and physiological dependency. Both d- and l- forms of Amphetamine are controlled substances. Urine based screening tests for drugs of abuse range from simple immunoassay tests to complex analytical procedures. The sensitivity and rapidity of immunoassays have made them the most accepted method of preliminary screening for drugs of abuse in urine. This allows the laboratory to eliminate the large number of negative specimens and focus on the smaller number of initially positive specimens.The QuickScreen One Step Amphetamine Test is a competitive immunoassay that is used to screen for the presence of Amphetamine in urine. It is a chromatographic absorbent device in which drugs or drug metabolites in a sample compete with drug / protein conjugate immobilized on a porous membrane for a limited number of antibody / dye conjugate binding sites. The test device employs a unique combination of monoclonal and polyclonal antibodies to selectively identify Amphetamine in urine with a high degree of confidence. In the procedure, the absorbent end of the test device is inserted into the urine sample. The urine is absorbed into the device by capillary action, mixes with the antibody / dye conjugate, and flows across the pre-coated membrane. When Amphetamine levels are below 1,000 ng/mL (the detection sensitivity of the test), antibody / dye conjugate binds to the drug / protein conjugate immobilized in the Test Region (T) of the device. This produces a colored Test Band that, regardless of its intensity, indicates a negative result. When Amphetamine levels are at or above 1,000 ng/mL, the free drug in the sample binds to the antibody / dye conjugate, preventing the antibody / dye conjugate from binding to the drug / protein conjugate immobilized in the Test Region (T) of the device. This prevents the development of a distinct colored band, indicating a potentially positive sample. In either case, a colored Control Band is produced in the Control Region (C) by a non-specific antibody-dye / conjugate reaction. The band serves as a built-in quality control device, demonstrating antibody recognition and reactivity, as well as confirming that the test is complete.
High Quality Assays with Reproducible and Reliable Results
High Quality Assays with Reproducible and Reliable Results
The One Step Barbiturates Screening Test is a rapid, qualitative immunoassay for the detection of Barbiturate compounds in urine. This assay is calibrated to react with Secobarbital at a cutoff concentration of 200 ng/mL. Other Barbiturates also react (see the “Cross-Reacting Substances” section of this test instruction sheet.) This assay is intended for professional use. This test provides only a preliminary test result. A more specific alternate testing method must be used in order to obtain a confirmed analytical result. Gaschromatography/mass spectrometry (GC/MS) is the preferred confirmatory method. Other confirmation methods are available. Clinical consideration and professional judgment should be applied to any drug of abuse test result, certainly when preliminary positive results are observed.Barbiturates form a large class of abused pharmaceuticals. These products are anxiolytic, sedative/hypnotic, anticonvulsant and anesthetic drugs. As CNS depressants, barbiturates exert effects on excitatory and inhibitory synaptic neurotransmission. Ultra short-acting barbiturates used for anesthesia, such as Pentobarbital, depress excitatory neuronal transmission to a greater extent than anti-convulsant barbiturates such as Phenobarbital. Barbiturates are rapidly and completely absorbed with nearly 100% bioavailability. Short-acting barbiturates are primarily excreted in urine as metabolites, while long-acting barbiturates are primarily excreted unchanged. Ratios of drugs to metabolites excreted vary, dependent upon duration of action. Urine based screening tests for drugs of abuse range from complex analytical procedures to simple immunoassay tests. The sensitivity and rapidity of the immunoassays have made them the most accepted method of preliminary screening for drugs of abuse in urine. This allows the laboratory to eliminate the large number of negative specimens and focus on the smaller number of initially positive samples.The One Step Barbiturates Screening Test is a competitive immunoassay that is used to screen for the presence of Barbiturates in urine. It is a chromatographic absorbent device in which drugs or drug metabolites in a sample compete with drug / protein conjugate immobilized on a porous membrane for a limited number of antibody /dye conjugate binding sites. The test device employs a unique combination of monoclonal and polyclonal antibodies to selectively identify Barbiturates in urine with a high degree of confidence. In the procedure, urine is added to the test device’s “SAMPLE” well with the aid of a plastic transfer pipette. The urine is absorbed into the device by capillary action, mixes with the antibody / dye conjugate, and flows across the pre-coated membrane. When sample Barbiturate levels are below 200 ng/mL (the detection sensitivity of the test), antibody / dye conjugate binds to the drug / protein conjugate immobilized in the Test Region (T) of the device. This produces a colored Test Band that, regardless of its intensity, indicates a negative result. When sample Barbiturate levels are at or above 200 ng/mL, the free drug in the sample binds to the antibody/dye conjugate, preventing the antibody / dye conjugate from binding to the drug / protein conjugate immobilized in the Test Region (T) of the device. This prevents the development of a distinct colored band, indicating a potentially positive sample. In either case, a colored Control Band is produced in the Control Region (C) by a non-specific antibody / dye conjugate reaction. This band serves as a built-in quality control device that demonstrates antibody recognition and reactivity as well as confirmation that the test result is valid.
The Occult Detect Test is a rapid chromatographic immunoassay for the qualitative detection of Human Occult Blood in feces.Many diseases can cause hidden blood in the feces. This is also known as Fecal Occult Blood (FOB), Human Occult Blood, or Human Hemoglobin. In the early stages, gastrointestinal problems such as colon cancer, ulcers, polyps, colitis, diverticulitis, and fissures may not show any visible symptoms, only occult blood. Traditional guaiac-based methods lack sensitivity and specificity, and also have diet restrictions prior to testing.1,2 The Occult Detect Test is a rapid test to qualitatively detect low levels of Fecal Occult Blood. The test uses a double antibody sandwich assay to selectively detect Fecal Occult Blood at 40 ng/mL or higher, or 4.8 μg/g feces. In addition, unlike guaiac assays, the accuracy of the test is not affected by the diet of the patients.The Occult Detect Test is a qualitative, lateral flow immunoassay for the detection of Human Occult Blood in feces. The membrane is precoated with anti-hemoglobin antibody on the test line region of the test. During testing, the specimen reacts with the particle coated with anti-hemoglobin antibody. The mixture migrates upward on the membrane chromatographically by capillary action to react with anti-hemoglobin antibody on the membrane and generate a coloured line. The presence of this coloured line in the test line region indicates a positive result, while its absence indicates a negative result. To serve as a procedural control, a coloured line will always appear in the control line region, indicating that the proper volume of specimen has been added and membrane wicking has occurred.
